NextCell Pharma: We’re in Flemingsberg because of the proximity to collaborative partners and the clinical research at Karolinska University Hospital.
At the forefront of medical innovation, NextCell Pharma is poised to revolutionize treatment paradigms. With a dual focus on developing therapies for autoimmune conditions and offering stem cell banking through Cellaviva, CEO Mathias Svahn leads the charge towards a future where incurable diseases become a thing of the past.
What is your business idea, what problem do you want to solve?
“Nextcell Pharma is a research and development company with two different business areas. One where we develop new treatments for autoimmune and inflammatory conditions. It’s here that our primary focus lies, Diabetes Type 1 that works as a model disease for us to later expand its use,” says Mathias Svahn, NextCell Pharma CEO.
“Our other business area is Cellaviva which offer expectant parents to save their children’s stem cells at birth, in a so-called family bank. The primary reason to save stem cells in a family bank is the possibility to take advantage of future new therapies and treatments.”
Where are you now?
“We’re now conducting a clinical drug trial of our drug candidate ProTrans. Something we do together with Karolinska Trial Alliance at Karolinska University Hospital here in Flemingsberg,” says Svahn.
“The aim is to demonstrate that the treatment is safe and discover whether patients’ own insulin production can be improved following a 12-month ProTrans-stem cell treatment.”
What are your plans for the future?
“Our goal is to develop new types of treatment for illnesses that we have not achieved previously, conditions that are currently incurable. Since last year, NextCell Pharma has been listed on Aktietorget to support our chances of reaching that goal,” says Svahn.
“At the same time, we want to offer many more families the opportunity to save their children’s stem cells at birth. We have recently signed an agreement with Nordic Tech House and Isabella Löwengrip to reach more parents to tell them about this opportunity.
Why are you in Flemingsberg?
“Flemingsberg is entirely the right place for us due to its closeness to co-operation partners and the clinical research at Karolinska University Hospital. Furthermore, this is the right place for us to grow given how Flemingsberg as a whole is flourishing and developing,” says Svahn.
Contact
Karolinska Science Park
Hälsovägen 7
141 57 Huddinge
08-735 55 95
OptiCell Solutions enters a research collaboration with Karolinska Institutet
With the goal of supporting academia, healthcare, and industry in developing the cell and gene therapies of the future, OptiCell Solutions established its operations in Flemingsberg last year. The company has now entered into [...]
Together for the Medicine of the Future – Karolinska ATMP Centre and ATMP Centre Uppsala strengthens collaboration in advanced therapies
A letter of intent has been signed between the Karolinska ATMP Center and the ATMP Center Uppsala to deepen collaboration in the field of advanced therapies (ATMP). The initiative was celebrated with a joint [...]
A national resource for tomorrow’s treatments – Karolinska ATMP Center is now inaugurated
With a clear message of hope for the future and a powerful spirit of collaboration, the Karolinska ATMP Center in Flemingsberg was inaugurated at the end of August. The center is a collaboration between [...]
ATMP Sweden – now also in Flemingsberg!
The ATMP Sweden association carries out dedicated work focused on national coordination and communication to accelerate the development, accessibility, and implementation of advanced therapies (ATMP). They now also have an office space at Novum Labs. From here, Henrik Simonsson, Communications and Operative Lead, can work on the association’s plans to take its operations to even more meaningful heights.
